European Journal of Cancer
短名 | Eur. J. Cancer |
Journal Impact | 7.41 |
国际分区 | ONCOLOGY(Q1) |
期刊索引 | SCI Q1中科院 1 区 |
ISSN | 0959-8049, 1879-0852 |
h-index | 245 |
国内分区 | 医学(1区)医学肿瘤学(2区) |
Top期刊 | 是 |
欧洲癌症杂志(包括 EJC 增刊)是一本国际综合性肿瘤学杂志,发表关于实验性肿瘤学、临床肿瘤学(内科、儿科、放射学、外科)、转化肿瘤学等方面的原创研究、社论评论、评论文章和新闻。癌症流行病学和预防。该杂志现在可以在线提交作者。
期刊主页投稿网址涉及主题 | 医学生物内科学遗传学癌症肿瘤科病理化学外科生物化学癌症研究化疗乳腺癌免疫学 |
出版信息 | 出版商: Elsevier Ltd,出版周期: Semimonthly,期刊类型: journal |
基本数据 | 创刊年份: 1990,原创研究文献占比: 86.95%,自引率:2.60%, Gold OA占比: 39.56% |
平均审稿周期 | 网友分享经验:平均1.0个月来源Elsevier官网:平均5.3周 |
平均录用比例 | 网友分享经验:约28% |
期刊引文格式
这些示例是对学术期刊文章的引用,以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章,因此这些字段是可选的。有些电子期刊不提供页面范围,而是列出文章标识符。在这种情况下,使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用,以及它们应该如何出现在您的参考文献中。
专利引用格式
最新文章
Computerizing the first step of the two-step algorithm in dermoscopy: A convolutional neural network for differentiating melanocytic from non-melanocytic skin lesions
2024-10-1
BAP1-mediated MAFF deubiquitylation regulates tumor growth and is associated with adverse outcomes in colorectal cancer
2024-10-1
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer
2024-10-1
Early versus late response to PD-1-based immunotherapy in metastatic melanoma
2024-10-1
PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitors
2024-10-1
The impact of inter-cycle treatment delays on 5-year all-cause mortality in early-stage breast cancer: a retrospective cohort study
2024-10-1
Assessing actionability and incidental findings of germline variants in two precision oncology trials
2024-10-1
5-Hydroxymethylcytosines in circulating cell-free DNA as a diagnostic biomarker for nasopharyngeal carcinoma
2024-10-1
Optimal Systemic Treatment and Real-World Clinical Application of ctDNA in Patients with Metastatic HER2-Mutant Lung Cancer
2024-10-1
Survival associated with the use of sentinel lymph node in addition to lymphadenectomy in early-stage cervical cancer treated with surgery alone: A sub-analysis of the Surveillance in Cervical CANcer (SCCAN) collaborative study
2024-9-12
Letter Re: PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitors
2024-9-1
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: a large real-life worldwide population
2024-9-1
Detection of circulating tumor DNA by tumor-informed whole-genome sequencing enables prediction of recurrence in stage III colorectal cancer patients
2024-9-1
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas
2024-9-1
Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: a real-world study including 3,922 patients from the French REALYSA cohort
2024-9-1
Comparing supplemental indications for cancer drugs approved in the US and EU
2024-9-1
Capmatinib Plus Nazartinib in Patients With EGFR-Mutated Non–Small Cell Lung Cancer
2024-9-1
Integrated Nomogram to Predict HER2 Expression in Breast tumor: Clinical, Ultrasound, and Photoacoustic Imaging Approaches
2024-9-1
Response to Letter re: Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: A Systematic Review and meta-analysis
2024-9-1
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas
2024-9-1
Corrigendum to “Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study” [Eur. J. Cancer, vol. 205 (2024) 114119]
2024-9-1
Adjustment for Imbalances in Baseline Characteristics in the MAGNITUDE Phase 3 Study Confirms the Clinical Benefit of Niraparib in Combination with Abiraterone Acetate Plus Prednisone in Patients with Metastatic Prostate Cancer
2024-9-1
Medical costs of lung cancer by stage, histology and first-line treatment modality in the Netherlands (2012–2021)
2024-9-1
The survival disparity between children and adolescents and young adults (AYAs) with Ewing sarcoma in the Netherlands did not change since the 1990s despite improved survival: A population-based study
2024-9-1
Precision cancer medicine platform trials: Concepts and design of AcSé-ESMART
2024-9-1
Systematic nutritional screening and assessment in older patients: Rationale for its integration into oncology practice
2024-9-1
TNM 8 staging system beyond p16: double HPV/p16 status is superior to p16 alone in predicting outcome in oropharyngeal squamous cell carcinoma
2024-9-1
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
2024-9-1
“Symptomatic” melanoma brain metastases: A call for clear definitions and adoption of standardized tools
2024-9-1
Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials
2024-9-1
The Role of CDCA2 in Tumor Genesis, Prognosis and Future Treatments
2024-9-1
Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615)
2024-9-1
Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)
2024-9-1
Oral ADAGRASIB associated with cetuximab unblocks obstructed colorectal cancer
2024-9-1
Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study
2024-9-1
Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma
2024-9-1
Evaluation of a medical student-delivered smoking prevention program utilizing a face-aging mobile app for secondary schools in Germany: The Education Against Tobacco Cluster-Randomized Controlled Trial
2024-9-1
Editorial Board
2024-9-1
Prevalence and size of pelvic sentinel lymph node metastases in endometrial cancer
2024-9-1
Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months
2024-9-1
Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: A review
2024-9-1
Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database
2024-9-1
Immunotherapy efficacy and toxicity: Reviewing the evidence behind patient implementable strategies
2024-9-1
Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: A national population-based cohort study using routine data
2024-9-1
Estimating cure and risk of death from other causes of cancer patients: EUROCARE-6 data on Head & Neck, Colorectal, and Breast cancers
2024-9-1
Protecting Cancer Survivors from Financial Discrimination throughout the EU: A cross-European Perspective
2024-9-1
HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome
2024-9-1
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): a single-arm, phase II study
2024-9-1
Treating cancer-associated venous thromboembolism: a practical approach
2024-9-1
An International Registry Study of Early-Stage NSCLC treatment variations (LUCAEUROPE) in Europe and the USA highlighting variations
2024-9-1
帮你贴心管理全部的文献
研飞ivySCI,高效的论文管理
投稿经验分享
分享我的经验,帮你走得更远